According to a meta-analysis of controlled trials published in the journal Obstetrics & Gynecology , selective serotonin reuptake inhibitors (SSRIs) are effective in reducing symptoms of severe premenstrual syndrome. premenstrual syndrome is common in women of childbearing age, and its most severe form, premenstrual dysphoric disorder, has a significant impact on quality of life of the woman who has it. If it is thought that SSRIs are the most effective pharmacological treatment, the meta-analysis of published evidence from clinical studies took a few years ago, new clinical trials have been published in that period.
The authors conclude that SSRIs are effective in reducing symptomatology of premenstrual syndrome and premenstrual dysphoric disorder, no significant differences between drugs studied. Continuous administration appeared to give a better response than intermittent administration, because the current thinking and practice prefer intermittent dosing, more comparative studies are needed to clarify this issue.
The authors conclude that SSRIs are effective in reducing symptomatology of premenstrual syndrome and premenstrual dysphoric disorder, no significant differences between drugs studied. Continuous administration appeared to give a better response than intermittent administration, because the current thinking and practice prefer intermittent dosing, more comparative studies are needed to clarify this issue.
To clarify terms, premestrual syndrome as a disorder exists, beyond of the sometimes obvious, mood swings in women. It is a condition of psychophysiological calls, ie by a malfunction (in this case, inappropriate activation duration and intensity) nervous system (specifically, the parasympathetic system).
SSRI stands under Selective Inhibitors of serotonin reuptake antidepressant primary today, but is also used in treating other disorders such as anxiety and OCD.
0 comments:
Post a Comment